#SFHS2609080AOrder of April 9, 2026, Amending Reimbursable Pharmaceutical Specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French regulation expands coverage for certain pharmaceutical treatments under the national health insurance. It allows a specific drug, RINVOQ, to be reimbursable for a new condition—giant cell arteritis—when used alongside corticosteroids, offering a treatment path for adults without better options.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Expanded reimbursement for RINVOQ to treat giant cell arteritis.
- Requires concurrent use with corticosteroids in specific conditions.
- Addresses patients with limited treatment alternatives.
Obligations
What this law requires
Add RINVOQ 15mg (upadacitinib) extended-release tablets (CIP code 34009 301 939 8 3, manufactured by ABBVIE) to the list of reimbursable pharmaceutical specialties for social insurance beneficiaries
Reimburse RINVOQ for treatment of giant cell arteritis in combination with tapering corticosteroid therapy in adult patients requiring corticosteroid-sparing therapy when no appropriate therapeutic alternative exists, including tocilizumab
Restrict RINVOQ reimbursement to patients meeting at least one of two clinical criteria: (1) corticosteroid dependence at doses ≥7.5 mg/day of prednisone causing recurrent relapses, or (2) necessity for rapid and early corticosteroid dose reduction due to corticosteroid intolerance or severe comorbidities
Verify absence of appropriate therapeutic alternatives (specifically including tocilizumab) before authorizing RINVOQ reimbursement for giant cell arteritis
Publish this order in the French Official Journal (Journal officiel de la République française)